Full Press Release Details
Clearmind Medicine Welcomes President
Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
Canada, April 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq:
CMND) ("Clearmind" or the "Company"), a clinical-stage psychedelic biotech company focused on the discovery and
development of novel, non-hallucinogenic, neuroplastogen-derived therapeutics to solve major under-treated health problems, today
commended President Donald J. Trump's Executive Order signed on April 18, 2026, titled Accelerating Medical Treatments for Serious
Mental Illness, which directs the U.S. Food and Drug Administration (FDA) to prioritize review processes for certain psychedelic drugs
designated as breakthrough therapies and expands patient access pathways.
"We are pleased to see psychedelic
medicines, including non-hallucinogenic neuroplastogens, gaining increasing mainstream recognition and regulatory momentum as promising
solutions for serious mental health conditions," said Dr. Adi Zuloff-Shani, Ph.D., Chief Executive Officer of Clearmind Medicine.
"This Executive Order highlights the growing acknowledgment at the highest levels of the urgent need to remove unnecessary barriers
and deliver innovative treatments to millions of Americans, especially veterans, suffering from treatment-resistant PTSD, depression,
and alcohol use disorder. It aligns closely with our mission to develop safe, effective, and scalable psychedelic-derived therapies that
harness the benefits of neuroplasticity without the p hallucinogenic experience."
The Executive Order builds directly on Clearmind
Medicine's recent milestone: in February 2026, the Company's proprietary compound MEAI (5-methoxy-2-aminoindane or (5-MeO-AI)
was explicitly named for the first time in bipartisan U.S. Congressional legislation (H.R. 7091 - Expanding Veterans' Access
to Emerging Treatments Act). This proposed legislation i would pave the way for VA-supported clinical trials and expanded access protocols
for innovative therapies targeting alcohol use disorder and related conditions.
"At Clearmind, we remain deeply committed
to rigorous, science-driven development of our lead candidate CMND-100 (MEAI) and our broader pipeline of psychedelic non-hallucinogenic
neuroplastogens," added Dr. Zuloff-Shani. "We look forward to continued collaboration with regulators, policymakers, and the
scientific community to ensure that breakthrough therapies reach the patients who need them most, swiftly, safely, and responsibly."
Clearmind Medicine is currently advancing
FDA-approved Phase I/IIa clinical trials of CMND-100 for alcohol use disorder at leading institutions including Yale School of Medicine
and Johns Hopkins University.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic
biotpharma company focused on the discovery and development of non-hallucinogenic, neuroplastogen-derived therapeutics to solve widespread
and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based neuroplastogens
and attempt to commercialize them as FDA regulated medicines, foods, or supplements.
The Company's intellectual portfolio
currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds
whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading
on Nasdaq under the symbol "CMND."
further information, visit: https://www.clearmindmedicine.com or contact:
Forward-Looking Statements:
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates"
and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using
forward-looking statements when it discusses its mission to develop safe, effective, and scalable non-hallucinogenic therapies that harness
the benefits of neuroplasticity without the psychedelic experience, how H.R. 7091, if passed, would potentially pave the way for VA-supported
clinical trials and expanded access protocols for innovative therapies targeting alcohol use disorder and related conditions, continued
collaboration with regulators, policymakers, and the scientific community to ensure that breakthrough therapies reach the patients who
need them most, swiftly, safely, and responsibly and the timing and progress of its clinical trials. Forward-looking statements are not
historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature,
are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance
that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is
expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could
cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description
of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with
the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in the Company's annual
report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements
speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual
results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information
except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference
should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated
by reference into this press release. Clearmind is not responsible for the contents of third-party websites.